Human uterine leiomyoma stem/progenitor cells expressing CD34 and CD49b initiate tumors in vivo
- PMID: 25658015
- PMCID: PMC4399295
- DOI: 10.1210/jc.2014-2134
Human uterine leiomyoma stem/progenitor cells expressing CD34 and CD49b initiate tumors in vivo
Abstract
Context: Uterine leiomyoma is the most common benign tumor in reproductive-age women. Using a dye-exclusion technique, we previously identified a side population of leiomyoma cells exhibiting stem cell characteristics. However, unless mixed with mature myometrial cells, these leiomyoma side population cells did not survive or grow well in vitro or in vivo.
Objective: The objective of this study was to identify cell surface markers to isolate leiomyoma stem/progenitor cells.
Design: Real-time PCR screening was used to identify cell surface markers preferentially expressed in leiomyoma side population cells. In vitro colony-formation assay and in vivo tumor-regeneration assay were used to demonstrate functions of leiomyoma stem/progenitor cells.
Results: We found significantly elevated CD49b and CD34 gene expression in side population cells compared with main population cells. Leiomyoma cells were sorted into three populations based on the expression of CD34 and CD49b: CD34(+)/CD49b(+), CD34(+)/CD49b(-), and CD34(-)/CD49b(-) cells, with the majority of the side population cells residing in the CD34(+)/CD49b(+) fraction. Of these populations, CD34(+)/CD49b(+) cells expressed the lowest levels of estrogen receptor-α, progesterone receptor, and α-smooth muscle actin, but the highest levels of KLF4, NANOG, SOX2, and OCT4, confirming their more undifferentiated status. The stemness of CD34(+)/CD49b(+) cells was also demonstrated by their strongest in vitro colony-formation capacity and in vivo tumor-regeneration ability.
Conclusions: CD34 and CD49b are cell surface markers that can be used to enrich a subpopulation of leiomyoma cells possessing stem/progenitor cell properties; this technique will accelerate efforts to develop new therapies for uterine leiomyoma.
Figures
Similar articles
-
Paracrine Pathways in Uterine Leiomyoma Stem Cells Involve Insulinlike Growth Factor 2 and Insulin Receptor A.J Clin Endocrinol Metab. 2017 May 1;102(5):1588-1595. doi: 10.1210/jc.2016-3497. J Clin Endocrinol Metab. 2017. PMID: 28324020 Free PMC article.
-
Overexpression of the truncated form of High Mobility Group A proteins (HMGA2) in human myometrial cells induces leiomyoma-like tissue formation.Mol Hum Reprod. 2015 Apr;21(4):330-8. doi: 10.1093/molehr/gau114. Epub 2014 Dec 26. Mol Hum Reprod. 2015. PMID: 25542836
-
Paracrine activation of WNT/β-catenin pathway in uterine leiomyoma stem cells promotes tumor growth.Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):17053-8. doi: 10.1073/pnas.1313650110. Epub 2013 Sep 30. Proc Natl Acad Sci U S A. 2013. PMID: 24082114 Free PMC article. Clinical Trial.
-
Uterine Leiomyoma Stem Cells: Linking Progesterone to Growth.Semin Reprod Med. 2015 Sep;33(5):357-65. doi: 10.1055/s-0035-1558451. Epub 2015 Aug 6. Semin Reprod Med. 2015. PMID: 26251118 Review.
-
Origin of Uterine Fibroids: Conversion of Myometrial Stem Cells to Tumor-Initiating Cells.Semin Reprod Med. 2017 Nov;35(6):481-486. doi: 10.1055/s-0037-1607205. Epub 2017 Nov 3. Semin Reprod Med. 2017. PMID: 29100235 Review. No abstract available.
Cited by
-
Extracellular vesicles and cancer stem cells: a deadly duo in tumor progression.Oncol Rev. 2024 Jul 18;18:1411736. doi: 10.3389/or.2024.1411736. eCollection 2024. Oncol Rev. 2024. PMID: 39091989 Free PMC article. Review.
-
Copper in Gynecological Diseases.Int J Mol Sci. 2023 Dec 17;24(24):17578. doi: 10.3390/ijms242417578. Int J Mol Sci. 2023. PMID: 38139406 Free PMC article. Review.
-
Novel Approaches to Possible Targeted Therapies and Prophylaxis of Uterine Fibroids.Diseases. 2023 Nov 1;11(4):156. doi: 10.3390/diseases11040156. Diseases. 2023. PMID: 37987267 Free PMC article. Review.
-
Current and Emerging Treatment Options for Uterine Fibroids.Drugs. 2023 Dec;83(18):1649-1675. doi: 10.1007/s40265-023-01958-6. Epub 2023 Nov 3. Drugs. 2023. PMID: 37922098 Review.
-
Developmental reprogramming of myometrial stem cells by endocrine disruptor linking to risk of uterine fibroids.Cell Mol Life Sci. 2023 Aug 31;80(9):274. doi: 10.1007/s00018-023-04919-0. Cell Mol Life Sci. 2023. Update in: Sci Prog. 2023 Oct-Dec;106(4):368504231215601. doi: 10.1177/00368504231215601. PMID: 37650943 Free PMC article. Updated.
References
-
- Walker CL, Stewart EA. Uterine fibroids: the elephant in the room. Science. 2005;308:1589–1592. - PubMed
-
- Mäkinen N, Mehine M, Tolvanen J, et al. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science. 2011;334:252–255. - PubMed
-
- Hodge JC, Morton CC. Genetic heterogeneity among uterine leiomyomata: insights into malignant progression. Hum Mol Genet. 2007;16:R7–R13. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials